Kuwait says its dealing with drone attacks

 Kuwait's Ministry of Defense said on Thursday it is working to repel drones that breached its airspace and are targeting "vital facilities." Earlier during the day, the ministry said it detected no new attacks in the past 24 hours.

The country was a frequent target of Iranian drone and missile strikes against US bases on its territory during the conflict that began on February 28. On the other hand, it remains unclear if Iran is behind the latest strikes. There have been no immediate reports of impacts or casualties.

Meanwhile, fighting continued between Israel and Hezbollah, following intense aerial attacks across Lebanon and the militant group's retaliatory rocket attacks.

https://breakingthenews.net/Article/Kuwait-says-its-dealing-with-drone-attacks/66040896

Putin declares Easter ceasefire in Ukraine

 Russian President Vladimir Putin declared a cessation of hostilities on the frontlines in Ukraine on the occasion of Orthodox Christian Eastern holidays. The ceasefire will begin at 4 pm on April 11 and last until the evening of April 12.

At the same time, Russia's Defense Minister Andrey Belousov and Chief of the General Staff of the Russian Armed Forces Valery Gerasimov instructed troops "to be prepared to counter any possible provocations by the enemy, as well as any aggressive actions." Moscow stated it assumes that Ukraine would abide by the truce, according to a statement published by the Kremlin.

On Wednesday, Ukrainian President Volodymyr Zelensky said his country was ready for a ceasefire if Russia halted its attacks.

https://breakingthenews.net/Article/Putin-declares-Easter-ceasefire-in-Ukraine/66040960

Treace Medical (NASDAQ: TMCI) raises 2026 sales view

Treace Medical Concepts, Inc. announced preliminary first quarter 2026 results and a leadership change. For the three months ended March 31, 2026, preliminary revenue is expected to be in the range of $47.0 million to $47.2 million. Preliminary cash, cash equivalents and marketable securities are expected to total about $51.9 million as of March 31, 2026, up from $48.4 million as of December 31, 2025 and a smaller increase in the first quarter of 2025.

The company updated its full-year 2026 revenue guidance to $202 million to $212 million, slightly raising the low end of the prior outlook to reflect continued case volume growth and headwinds from product and price mix in its expanded bunion portfolio.

https://www.stocktitan.net/sec-filings/TMCI/8-k-treace-medical-concepts-inc-reports-material-event-d2b42a218016.html

Zentalis selects 400mg once-daily 5:2 azenosertib monotherapy pivotal dose for ovarian cancer trials

 

Zentalis selects 400mg once-daily 5:2 azenosertib monotherapy as pivotal dose for DENALI and ASPENOVA ovarian cancer trials

• DENALI is a Phase 2 trial and ASPENOVA a Phase 3 trial in ovarian cancer
• Both trials are in Cyclin E1-positive platinum-resistant ovarian cancer
• Dose selection was based on interim DENALI Part 2a data

https://finviz.com/quote.ashx?t=ZNTL&p=d

'Putin's Envoy Meets Trump Team'

 

Kirill Dmitriev, Russian President Vladimir Putin's special envoy, is in the U.S. to meet with members of President Trump's administration. Discussions focus on a peace deal for Ukraine and U.S.-Russia economic cooperation. The visit also precedes a U.S. decision on extending sanctions relief for Russian oil.

Kirill Dmitriev, the special envoy for Russian President Vladimir Putin, is visiting the United States to engage in high-level discussions with the Trump administration.

The talks aim to explore avenues for a peace deal concerning Ukraine and improved economic cooperation between the two global powers.

This diplomatic effort occurs before a critical U.S. decision on April 11 regarding the extension of sanctions relief on Russian oil, a topic likely to be included in the discussions.

https://www.devdiscourse.com/article/headlines/3868576-high-stakes-diplomacy-putins-envoy-meets-trump-team

STAAR Surgical Shares Jump on Blowout $90M Sales Outlook

 STAAR Surgical STAA +24.21%  stock surged more than 25% on Thursday after the ophthalmic implant maker projected first-quarter net sales would top $90 million, more than double the year-ago period.

STAAR Surgical stock jumped as investors reacted to the unexpectedly strong preliminary outlook.

The company attributed the sharp increase largely to a recovery in China, where distributor inventory reductions had weighed on results last year. STAAR Surgical stock also benefited from continued double-digit expansion in the Americas region. STAAR Surgical stock saw improved operating leverage and cost management that are expected to lift adjusted EBITDA meaningfully.

Management noted that the sales rebound in China was accompanied by steady demand across the Americas portfolio. STAAR Surgical stock moved higher even as executives acknowledged lingering pressure from geopolitical tensions and uneven economic conditions in parts of the Middle East, Europe, and Asia-Pacific.

https://www.gurufocus.com/news/8785319/staar-surgical-shares-jump-25-on-blowout-90m-sales-outlook

Invivyd (IVVD) expands Covid Phase 3, pushes potent measles antibody toward clinic

Invivyd, Inc. provides detailed updates on its COVID-19 antibody program and unveils a new measles antibody candidate. The pivotal Phase 3 DECLARATION study of VYD2311 for pre-exposure COVID-19 prophylaxis has been upsized by about 500 participants beyond an initial 1,818, after a pre-specified, conservative, blinded sample size re-estimation showed enough events to support high-end efficacy targets. Top-line data are now expected in the third quarter of 2026, with a pediatric VYD2311 study in children 0–11 years, called DRUMMER, planned only if DECLARATION is successful. Invivyd also introduces VMS063, a highly potent, half-life-extended measles monoclonal antibody targeting the conserved Fusion protein, showing picogram- to low-nanogram-per-milliliter neutralization in vitro across key measles lineages. VMS063 has entered IND-enabling work for near-term clinical development, aimed at treatment and prophylaxis in high-risk groups amid rising U.S. measles cases and waning herd immunity.

https://www.stocktitan.net/sec-filings/IVVD/8-k-invivyd-inc-reports-material-event-aafaf5db8932.html